Overview

  • Product nameAnti-AlaRS antibody
    See all AlaRS primary antibodies
  • Description
    Mouse polyclonal to AlaRS
  • Tested applicationsSuitable for: WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Full length Human protein (NP_001596.2)

  • Positive control
    • WB: Human liver or HeLa cell lysate. ICC/IF: HeLa cells.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: None
    Constituents: 1X PBS, pH 7.2
  • Concentration information loading...
  • PurityProtein A purified
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab89106 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 107 kDa.
ICC/IF Use a concentration of 10 µg/ml.

Target

  • FunctionCatalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain.
  • Involvement in diseaseCharcot-Marie-Tooth disease 2N
  • Sequence similaritiesBelongs to the class-II aminoacyl-tRNA synthetase family.
  • DomainConsists of three domains; the N-terminal catalytic domain, the editing domain and the C-terminal C-Ala domain. The editing domain removes incorrectly charged amino acids, while the C-Ala domain, along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs.
    The C-terminal C-Ala domain (residues 756 to 968), along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs. The human domain can be used in vitro to replace the corresponding domain in E.coli.
  • Post-translational
    modifications
    ISGylated.
  • Cellular localizationCytoplasm.
  • Information by UniProt
  • Database links
  • Alternative names
    • AARS antibody
    • AI316495 antibody
    • Alanine tRNA ligase 1, cytoplasmic antibody
    • Alanine tRNA ligase antibody
    • Alanine tRNA ligase cytoplasmic antibody
    • Alanine--tRNA ligase antibody
    • Alanyl tRNA synthetase antibody
    • Alanyl tRNA synthetase cytoplasmic antibody
    • Alanyl-tRNA synthetase antibody
    • AlaRS antibody
    • C76919 antibody
    • CMT2N antibody
    • cytoplasmic antibody
    • EC 6.1.1.7 antibody
    • MGC37368 antibody
    • Renal carcinoma antigen NY REN 42 antibody
    • Renal carcinoma antigen NY-REN-42 antibody
    • SYAC_HUMAN antibody
    see all

Anti-AlaRS antibody images

  • ab89106 at 10 µg/ml staining AlaRS by immunofluorescence in PFA-fixed, permeabilized HeLa cells.
  • Anti-AlaRS antibody (ab89106) at 1 µg/ml + Human liver lysate at 50 µg

    Predicted band size : 107 kDa
  • Anti-AlaRS antibody (ab89106) at 1 µg/ml + HeLa cell lysate at 50 µg

    Predicted band size : 107 kDa
  • All lanes : Anti-AlaRS antibody (ab89106) at 1 µg/ml

    Lane 1 : AlaRS-transfected 293T cell lysate
    Lane 2 : non transfected lysate

    Lysates/proteins at 25 µg per lane.


    Predicted band size : 107 kDa

References for Anti-AlaRS antibody (ab89106)

ab89106 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab89106.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"